Related Experiment Video
Updated: Jul 17, 2026
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
Published on: August 9, 2019
Umbilical cord blood transplantation for myeloid malignancies
Claudio G Brunstein1, K Scott Baker, John E Wagner
1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA. bruns072@umn.edu
Purpose Of Review:
To review the available data on the outcomes of pediatric and adult patients with acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia after umbilical cord blood transplantation.
Recent Findings:
The literature shows that after umbilical cord blood transplantation the relapse rate, disease-free survival and overall survival of patients with myeloid malignancies is similar to other hematopoietic stem cells sources. Disease status at the time of transplantation is found in several studies to be a very important determinant of long-term outcome. Newer strategies such as double umbilical cord blood transplant and utilization of nonmyeloblative conditioning regimens show promising results.
Summary:
Umbilical cord blood is a valuable alternative source of hematopoietic stem cells for transplantation of patients with myeloid malignancies who need an allogeneic transplant, but lack a suitable sibling donor.
More Related Videos
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...